Table I.
Summary of data for the 7 patients with PAD and COVID-19
| Patient No. | PAD | Age (y) | Sex | COVID-19 |
||||
|---|---|---|---|---|---|---|---|---|
| Clinical symptoms | Days | Treatment | ICU | Outcome | ||||
| 1 | ARA | 56 | M | No symptoms | 0 | Hydroxychloroquine, azithromycin, darunavir/cobicistat | No | Recovery |
| 2 | XLA | 34 | M | High fever | 3 | Hydroxychloroquine, ceftriaxone, lopinavir/ritonavir | No | Recovery |
| 3 | CVID | 59 | F | High fever, dyspnea | 20 | Hydroxychloroquine, azithromycin, tocilizumab | Yes | Death |
| 4 | CVID | 32 | F | High fever, dyspnea | 16 | Hydroxychloroquine, darunavir/ritonavir, tocilizumab | No | Recovery |
| 5 | CVID | 57 | M | High fever, dyspnea | 25 | Hydroxychloroquine, lopinavir/ritonavir, remdesivir methylprednisolone. | Yes | Recovery |
| 6 | CVID | 52 | M | High fever, dyspnea | 21 | Hydroxychloroquine, azithromycin, lopinavir/ritonavir, | No | Recovery |
| 7 | CVID | 41 | M | High fever, dyspnea | 19 | Hydroxychloroquine, piperacillin/tazobactam, lopinavir/ritonavir, tocilizumab, remdesivir | Yes | Recovery |
ARA, Autosomal recessive agammaglobulinemia; F, female; ICU, intensive care unit; M, male; XLA, X-linked agammaglobulinemia.